CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...